CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings24/10/2017 by Intellectual Property Watch Leave a CommentShare this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)IP-Watch and its Global Health Policy News are non-profit independent news services and depend on subscriptions. To access all of our content, please subscribe now. You may also offer additional support with your subscription, or donate.CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. According to CARB-X, its portfolio is “the world’s largest and most scientifically diverse portfolio of early development antibiotics and rapid diagnostics to treat the most serious drug-resistant bacterial infections, often referred to as superbugs.”CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) was launched in July 2016. It currently funds projects in 6 countries and “is working to expand its pipeline with the best science from around the world.”CARB-X’s mission is to: “Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $455 million in BARDA funds with matching funds from Wellcome Trust.”Antimicrobial resistance is on the rise globally, and CARB-X represents a leading effort to address potential shortages of new types of antimicrobials in the pipeline. It has partnered with 19 companies in six countries so far.Today’s press release is reprinted below:Amicrobe’s Amicidin-β program is the first topical antimicrobial in CARB-X’s portfolio and could potentially be used to treat infected tissue in surgical and emergency settings, as well as in post-disaster scenarios involving large numbers of injured peopleCARB-X announced today an award of up to $2.48 million to Amicrobe Inc. to accelerate the development of a new bioengineered antimicrobial designed for direct application to contaminated and infected tissues, including those of surgery and trauma. The award commits funding of up to $2.48 million in an initial period, with the possibility of up to $3.76 million more based on the achievement of milestones.The Amicrobe project brings to 20 the number of R&D programs in CARB-X portfolio. Click here to read more. CARB-X is planning to announce other new awards in the coming weeks, continuing to build the world’s largest and most scientifically diverse R&D portfolio in the battle against drug-resistant bacteria.Find out more about CARB-X news at www.carb-x.org/ or follow us on twitter @CARB_X—The 12 October press release is accessible below:On 12 October, CARB-X announced an award of $3.8 million to Entasis Therapeutics “to accelerate the development of a new antibiotic class to treat serious drug-resistant Gram-negative bacterial infections.” The award commits initial funding of up to $3.8 million with the possibility of up to $6.3 million more if milestones are met. Share this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Related"CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.